Semaglutide Side Effects: What the Trials and Label Report

Semaglutide side effects are overwhelmingly gastrointestinal, and they track dose changes rather than duration. Nausea, vomiting, diarrhoea, and constipation dominate, peak after each increase, and generally settle as a dose is held.

That pattern follows from the mechanism, which is why the escalation schedule is deliberately slow.

Why the effects are gastrointestinal

GLP-1 receptor activity slows gastric emptying and acts on appetite signalling. The fullness that reduces intake and the nausea that makes people uncomfortable are the same mechanism seen from two angles.

That is also why the effects cannot simply be engineered away — reducing them means reducing the activity that produces the benefit. See the comparison with tirzepatide for how a second receptor changes that balance.

The common effects

Escalating slowly is the main lever. The semaglutide dosage chart sets out the steps and why each is held for weeks.

The ones that are not gastrointestinal

• Thyroid C-cell tumours. A boxed warning from rodent data, with contraindication for personal or family history of medullary thyroid carcinoma or MEN2. Whether it translates to humans is unestablished, which is why the warning is precautionary.

• Pancreatitis. Reported with this class; severe persistent abdominal pain warrants urgent assessment rather than waiting.

• Gallbladder disease. Associated with rapid weight reduction generally.

• Hypoglycaemia. Mainly when combined with insulin or a sulfonylurea.

• Diabetic retinopathy. Rapid glucose improvement can transiently worsen existing retinopathy.

• Delayed gastric emptying before anaesthesia. A documented consideration when planning procedures involving sedation.

How long they last

The usual pattern is that effects appear or intensify within days of an increase and ease over the following weeks at a stable dose — then return at the next step. People frequently describe the maintenance dose as considerably more comfortable than the climb to it.

Compounded and research-grade material

Everything above describes the approved product. Compounded and research-grade semaglutide sit outside that channel and add failure modes no trial addresses: identity, purity, content against label, and sterility.

The COA guide covers what can be verified, and the vendor guide what cannot.

Frequently asked questions

Do the side effects go away?

They typically ease at a stable dose and return at the next increase. That cycle is the normal pattern.

Are they worse than tirzepatide?

Both are dominated by the same category of effect. SURMOUNT-5 compared them directly and both were characterised by gastrointestinal effects, even though efficacy differed.

What warrants urgent attention?

Severe persistent abdominal pain, signs of an allergic reaction, or vision changes are outside the ordinary adjustment pattern and warrant medical assessment.